Home » CELERA GENOMICS RECEIVES NIH GRANT TO DEVELOP AND COMMERCIALIZE AVIAN FLU DIAGNOSTIC TEST
CELERA GENOMICS RECEIVES NIH GRANT TO DEVELOP AND COMMERCIALIZE AVIAN FLU DIAGNOSTIC TEST
August 21, 2006
Celera Genomics, an Applera Corporation business, announced that the National Institutes of Health (NIH) has awarded Celera approximately $900,000 to develop and commercialize an in vitro diagnostic (IVD) test for the highly pathogenic influenza A/H5 virus (Asian lineage, H5N1). The test Celera plans to develop
will be based on the Primer and Probe Set and protocols used in the test from
the U.S. Health and Human Services' Centers for Disease Control and Prevention
(CDC) recently cleared by the U.S. Food and Drug Administration (FDA).
Business
Wire
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct